Triterpenoid ellagic tannin compound for inhibiting alpha-glucosidase as well as preparation and application thereof

By extracting, isolating, and purifying the triterpenoid ellagitannin compound castanopsinin J from the plant Conophytum argentis, the problem of the lack of α-glucosidase inhibitors in the prior art has been solved, enabling the development of an effective drug for the treatment of diabetes.

CN118909019APending Publication Date: 2024-11-08GUANGXI INST OF BOTANY THE CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410921688.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-10
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The lack of triterpenoid ellagitannins with α-glucosidase inhibitory activity isolated from *Achnatherum sp.* in the current technology leads to insufficient selection of drugs for the treatment of diabetes.

Method used

Castanopsinin J, a triterpenoid ellagitannin compound with α-glucosidase inhibitory activity, was extracted and isolated from the plant Conophytum argentis. Its pharmacological activity was purified and verified by a specific chromatographic method.

Benefits of technology

The obtained castanopsinin J showed significant α-glucosidase inhibitory activity, with an IC50 value of 0.0258±0.008 mg/mL, indicating its potential application as a hypoglycemic drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909019A_ABST
    Figure CN118909019A_ABST
Patent Text Reader

Abstract

The invention relates to a triterpenoid ellagic tannin compound for inhibiting alpha-glucosidase as well as preparation and application thereof. The triterpenoid ellagic tannin compound for inhibiting the alpha-glucosidase comprises a compound as shown in a formula (I) or a medicinal salt or a medicinal esterification derivative as shown in the formula (I): # imgabs0. The triterpenoid ellagic tannin component castanopsin J with the alpha-glucosidase inhibiting activity, which is provided by the invention, is separated from leaves of tapioca of a fagaceae tapioca plant, for the first time; according to the present invention, the in vitro pharmacological experiment results prove that the IC50 value of the alpha-glucosidase is 0.0258 + / -0.008 mg / mL, such that the good alpha-glucosidase inhibition activity is provided; therefore, the triterpenoid ellagic tannin component castanopsinin J, or the derivative thereof, or the medicinal salt thereof can be used for hypoglycemic drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medicines, and in particular to a triterpene ellagitannin compound capable of inhibiting alpha-glucosidase, and a preparation method and application thereof. Background Art

[0002] Diabetes is a chronic disease caused by genetic or environmental factors, which seriously threatens human life and health due to defects in insulin secretion or its biological function. Diabetes is divided into type 1, type 2 and other types. Among the oral antihyperglycemic drugs for the treatment of type 2 diabetes, the mechanism of action of α-galucosidase inhibitors is to inhibit α-glucosidase on the brush villi of the small intestinal wall, delaying the hydrolysis of polysaccharides into glucose and other monosaccharides, which can slow down the rise of blood sugar after meals and ultimately achieve the effect of treating diabetes.

[0003] Triterpenoid ellagitannins are a class of compounds that have been discovered rarely so far. They are produced by esterification of pentacyclic triterpenes with unique spatial structures and ellagitannins with unique polyphenolic structures. Modern pharmacological studies have shown that pentacyclic triterpenes and ellagitannins are widely distributed in plants and each has strong biological activity. However, it is worth looking forward to whether triterpenoid ellagitannins synthesized by esterification in plants will have synergistic effects or other unique activities in terms of biological activity.

[0004] Castanopsis calathiformis is a plant of the genus Castanopsis in the Fagaceae family, native to southern Yunnan and southeastern Tibet. Currently, there is no report on the isolation of highly oxidized triterpenoid ellagitannin castanopsinin J with α-glucosidase inhibitory activity from Castanopsis calathiformis.

[0005] In view of this, the present invention provides a preparation method and application of an α-glucosidase inhibitory active ingredient from the plant of Tapioca pearls, which provides a new choice for diabetes treatment drugs and makes up for the shortcomings of the prior art. Summary of the invention

[0006] The technical problem to be solved by the present invention is to provide a triterpene ellagitannin compound capable of inhibiting alpha-glucosidase and the preparation and application thereof.

[0007] The technical solution of the present invention to solve the above technical problems is as follows:

[0008] In a first aspect, a triterpene ellagitannin compound that inhibits α-glucosidase is provided. The triterpene ellagitannin compound that inhibits α-glucosidase comprises a compound as shown in formula (I) or a pharmaceutically acceptable salt or pharmaceutically acceptable esterified derivative of formula (I):

[0009]

[0010] Among them, the pharmaceutically acceptable salt is selected from the salt formed by triterpenoid ellagitannins and organic acids or inorganic acids; the pharmaceutically acceptable esterified derivative is a pharmaceutically acceptable derivative of triterpenoid ellagitannins components having α-glucosidase inhibitory activity.

[0011] The beneficial effects of the present invention are as follows: the highly oxidized triterpenoid ellagitannin component castanopsinin J with α-glucosidase inhibitory activity provided by the present invention is isolated for the first time from the leaves of the Fagaceae plant Castanopsinin japonica; the ellagitannin component castanopsinin J provided by the present invention is confirmed by in vitro pharmacological experiments to have an IC of α-glucosidase 50 The value is 0.0258±0.008 mg / mL, indicating that it has good α-glucosidase inhibitory activity; therefore, the triterpenoid ellagitannin component castanopsinin J, or its derivatives, or its pharmaceutically acceptable salts can be used as hypoglycemic drugs.

[0012] Based on the above technical solution, the present invention can also be improved as follows.

[0013] In a second aspect, a use of a triterpene ellagitannin compound for inhibiting α-glucosidase is provided, wherein the triterpene ellagitannin compound for inhibiting α-glucosidase is used to prepare a drug for inhibiting α-glucosidase.

[0014] Furthermore, the drug treats elevated blood sugar caused by genetic or environmental factors by inhibiting α-glucosidase.

[0015] In the third aspect, a drug for inhibiting α-glucosidase includes the triterpene ellagitannin compound for inhibiting α-glucosidase, and may also include castanopsinin A, castanopsinin B, 3,24-(S)-HHDP-2α,3β,23,24-tetrahydroxytaraxastan-28,20β-olide, 3,24-di-O-galloyl-2α,3β,23,24-tetrahydroxyurs-12-en-28-oic acid28-O-β-D-glucopyranoside, etc.

[0016] Furthermore, it also includes pharmaceutically acceptable pharmaceutical excipients and / or carriers.

[0017] Furthermore, the dosage form of the drug is any one of granules, capsules, nanoformulations, controlled-release preparations, and sustained-release preparations. The above-mentioned dosage forms can be prepared by conventional methods.

[0018] In a fourth aspect, a preparation of a triterpene ellagitannin compound that inhibits α-glucosidase comprises the following steps:

[0019] (1) taking leaves of the Chinese wolfberry, crushing them, adding an alcohol compound to extract them, and concentrating the extract obtained by the extraction under reduced pressure to obtain a crude extract;

[0020] (2) adding water to the crude extract for flotation and then defatting, and then concentrating under reduced pressure to obtain a defatted water extract;

[0021] (3) Separating the defatted water extract by chromatography on a Sephadex LH-20 gel column, an MCI gel CHP 20P column and a Diaion HP20SS column in turn, and eluting with a methanol-water mixed solution gradient to obtain a triterpene ellagitannin compound that inhibits α-glucosidase.

[0022] The beneficial effects of adopting the above scheme are as follows: the present invention uses the leaves of Castanopsis scoparia as raw materials to extract and separate α-glucosidase inhibitory components, the preparation method is simple, the operation is easy, and the leaves are used as raw materials for extraction, the resources are abundant, and there is good potential economic benefit, and the obtained α-glucosidase inhibitory component castanopsinin J is stable in nature and easy to store; the α-glucosidase inhibitory activity is good, and it is expected to be used as a lead compound to develop new diabetes treatment drugs.

[0023] Furthermore, in step (1), the ratio of the alcohol to the leaves of the tapioca pearl is (40-80) L: (5.5-10) kg;

[0024] The alcohol includes at least one of ethanol, methanol and propanol.

[0025] Furthermore, in step (2), the volume ratio of the crude extract to water in the water flotation is 1 to 2; the degreasing is specifically performed by using petroleum ether for degreasing, the volume ratio of the crude extract to the petroleum ether is 0.5 to 1, and the number of degreasing is 2 to 4 times.

[0026] Furthermore, in step (3), the volume content of methanol in the methanol-water mixed solution used for the Sephadex LH-20 gel column chromatography separation is 0%, 20%, 40%, 60%, 80%, and 100% respectively;

[0027] In step (3), the volume content of methanol in the methanol-water mixed solution used for the MCI gel CHP 20P column chromatography separation is 0%, 20%, 40%, 60%, 80%, and 100% respectively;

[0028] In step (3), the volume contents of methanol in the methanol-water mixed solution used for the Diaion HP20SS column chromatography separation are 0%, 10%, 20%, 30%, 40%, 50%, and 60% respectively. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 The compound castanopsinin J 1 H-NMR (500MHz, CD3OD) spectrum;

[0030] Figure 2 The compound castanopsinin J 13 C-NMR (125MHz, CD3OD) spectrum;

[0031] Figure 3 is the HSQC spectrum of compound castanopsinin J;

[0032] Figure 4 is the HMBC spectrum of compound castanopsinin J;

[0033] Figure 5 The compound castanopsinin J 1 H- 1 H COSY spectrum;

[0034] Figure 6 This is the HR-EIMS spectrum of compound castanopsinin J. DETAILED DESCRIPTION

[0035] The principles and features of the present invention are described below, and the examples are only used to explain the present invention and are not used to limit the scope of the present invention. If no specific technology or conditions are specified in the embodiments, the technology or conditions described in the literature in this field or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.

[0036] Example 1

[0037] 1. Isolation and purification of triterpenoid ellagitannin compound (castanopsinin J)

[0038] The castanopsinin J of the present invention is a triterpene ellagitannin component compound extracted, separated and purified from the leaves of the plant Castanopsis calathiformis collected from Matang Town, Wenshan City, Yunnan Province. The separation and purification process is as follows:

[0039] 5.5 kg of dried Aconite leaves were crushed and then soaked and extracted with 40 L of 80% methanol for 3 times, each time for 7 days, and filtered. The filtrates were combined and concentrated under reduced pressure to obtain an aqueous solution, which was concentrated under reduced pressure to obtain a crude extract. The crude extract was floated with 1.6 L of water and then defatted with petroleum ether for 3 times (1.6 L of petroleum ether was added each time). The defatted aqueous solution was concentrated under reduced pressure to obtain the water layer, i.e., the water extract. The defatted water extract was separated by Sephadex LH-20 (10.0 cm × 39.0 cm) column chromatography, and the eluent was a mixture of methanol and water with a methanol volume content of 0%, 20%, 40%, 60%, 80%, and 100% in sequence, with a gradient of 4 L each. The same components were combined using a silica gel thin layer plate (TLC) to monitor and obtain 8 fractions (Fr. 1 to 8).

[0040] Fr.4 (269.2 g) was separated by MCI gel CHP 20P (8.0 cm×34.0 cm) column chromatography. The eluent was a mixture of methanol and water with a methanol volume content of 0%, 20%, 40%, 60%, 80%, and 100%, respectively, with each gradient being 2 L. The same components were monitored and combined using silica gel thin layer plate (TLC) to obtain 8 fractions (Fr.4.1~4.8).

[0041] Fr.4.8 (48.3 g) was separated by Diaion HP20SS (2.0 cm × 28.0 cm) column chromatography, and the eluent was a mixture of methanol and water with a methanol content of 0%, 10%, 20%, 30%, 40%, 50%, and 60% by volume, each gradient of 1 L. The same components were combined and monitored by silica gel thin layer plate (TLC), and compound castanopsinin J (54 mg) was isolated.

[0042] 2. Identification of triterpenoid ellagitannin compounds

[0043] Figure 1 The compound castanopsinin J 1 H-NMR spectrum; Figure 2 The compound castanopsinin J 13 C-NMR spectrum; Figure 3 is the HSQC spectrum of compound castanopsinin J; Figure 4 is the HMBC spectrum of compound castanopsinin J; Figure 5 The compound castanopsinin J 1 H- 1 H COSY spectrum; Figure 6This is the HR-EIMS spectrum of compound castanopsinin J. Castanopsinin J is a white amorphous powder with bright spots under 254nm ultraviolet light and brown spots after reaction with 1% FeCl3-EtOH color developer. 1 H-NMR (500MHz, CD3OD), 13 C-NMR (125 MHz, CD3OD) data are shown in Table 1 below.

[0044] Table 1 NMR data of compound castanopsinin J (in CD3OD)

[0045]

[0046] Based on the comprehensive analysis of the above spectral data, the structural formula of the compound is deduced as shown in formula (I):

[0047]

[0048] Example 2

[0049] 1. Activity detection

[0050] 20×PBS phosphate buffer solution was prepared to a concentration of 50mM and a pH value of 6.8. 1mmol / L p-nitrophenyl-α-D-pyranoglucoside (PNPG) was used as a substrate. The purchased 10U / mg α-glucosidase was prepared into an enzyme solution with an enzyme activity of 0.5U / mL for standby use, and acarbose was used as a positive control. 50μL PBS phosphate buffer was added to a 96-well plate, and 40μL samples of different concentrations (triterpenoid ellagitannin compounds that inhibit α-glucosidase) and PBS were added to the enzyme reaction group and the blank group, and 10μL of 0.5U / mL α-glucosidase was added. After mixing, incubated at 37°C for 5min, and then 20μL of 1mmol / L PNPG solution was added. After reacting in a 37°C incubator for 30min, the absorbance was measured at a wavelength of 405nm using an enzyme reader. According to the formula: α-glucosidase inhibition rate = [1-(A 反应组 -A 反应对照组 ) / (A 空白组 -A 空白对照组 )] × 100%, and calculate the enzyme activity inhibition rate. The above experiment was repeated 3 times in parallel, and the average value was taken to calculate the IC 50 value.

[0051] 2. Activity Results

[0052] In vitro pharmacological experiments have confirmed that the IC of the positive drug acarbose 50 The IC value of castanopsinin J was 1.058±0.051mg / mL.50 It is 0.0258±0.008mg / mL, showing extremely strong α-glucosidase inhibitory activity, and can be effectively used to prepare hypoglycemic drugs, opening up a new approach to hypoglycemic drugs and a new use of the Tapioca pearls plant, with significant economic and social benefits.

[0053] In summary, the highly oxidized triterpenoid ellagitannin component castanopsinin J with α-glucosidase inhibitory activity provided by the present invention is isolated for the first time from the leaves of the Fagaceae plant Castanopsinin japonica; the ellagitannin component castanopsinin J provided by the present invention has been confirmed by in vitro pharmacological experiments to have an IC of α-glucosidase. 50 The value is 0.0258±0.008 mg / mL, indicating that it has good α-glucosidase inhibitory activity; therefore, the triterpenoid ellagitannin component castanopsinin J, or its derivatives, or its pharmaceutically acceptable salts can be used as hypoglycemic drugs.

[0054] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A triterpene ellagitannin compound for inhibiting α-glucosidase, characterized in that: The triterpene ellagitannin compound that inhibits α-glucosidase includes a compound as shown in formula (I) or a pharmaceutically acceptable salt or pharmaceutically acceptable esterified derivative of formula (I):

2. An application of a triterpene ellagitannin compound for inhibiting α-glucosidase, characterized in that: The triterpene ellagitannin compound for inhibiting α-glucosidase according to claim 1 is used for preparing a drug for inhibiting α-glucosidase.

3. The use of a triterpene ellagitannin compound for inhibiting α-glucosidase according to claim 2, characterized in that: The drug treats the increase of blood sugar caused by genetic or environmental factors by inhibiting α-glucosidase.

4. A drug for inhibiting α-glucosidase, characterized in that: The invention comprises the triterpene ellagitannin compound for inhibiting α-glucosidase as claimed in claim 1.

5. A drug for inhibiting α-glucosidase according to claim 4, characterized in that: Also included are pharmaceutically acceptable excipients and / or carriers.

6. A drug for inhibiting α-glucosidase according to claim 4, characterized in that: The dosage form of the medicine is any one of granules, capsules, nano preparations, controlled release preparations and sustained release preparations.

7. The preparation of a triterpene ellagitannin compound for inhibiting α-glucosidase according to claim 1, characterized in that: The steps include: (1) taking leaves of the Chinese wolfberry, crushing them, adding an alcohol compound to extract them, and concentrating the extract obtained by the extraction under reduced pressure to obtain a crude extract; (2) adding water to the crude extract for flotation and then defatting, and then concentrating under reduced pressure to obtain a defatted water extract; (3) Separating the defatted water extract by chromatography on a Sephadex LH-20 gel column, an MCI gel CHP 20P column and a Diaion HP20SS column in turn, and eluting with a methanol-water mixed solution gradient to obtain a triterpene ellagitannin compound that inhibits α-glucosidase.

8. The preparation of a triterpene ellagitannin compound for inhibiting α-glucosidase according to claim 7, characterized in that: In step (1), the ratio of the alcohol to the leaves of the tapioca pearl is (40-80) L: (5.5-10) kg; The alcohol includes at least one of ethanol, methanol and propanol.

9. The preparation of a triterpene ellagitannin compound for inhibiting α-glucosidase according to claim 7, characterized in that: In step (2), the volume of the crude extract and water in the water flotation is 1 to 2; the degreasing is specifically: degreasing is performed using petroleum ether, the volume ratio of the crude extract to the petroleum ether is 0.5 to 1, and the number of degreasing is 2 to 4 times.

10. The preparation of a triterpene ellagitannin compound for inhibiting α-glucosidase according to claim 7, characterized in that: In step (3), the volume content of methanol in the methanol-water mixed solution used for the Sephadex LH-20 gel column chromatography separation is 0%, 20%, 40%, 60%, 80%, and 100% respectively; In step (3), the volume content of methanol in the methanol-water mixed solution used for the MCI gel CHP 20P column chromatography separation is 0%, 20%, 40%, 60%, 80%, and 100% respectively; In step (3), the volume contents of methanol in the methanol-water mixed solution used for the Diaion HP20SS column chromatography separation are 0%, 10%, 20%, 30%, 40%, 50%, and 60% respectively.